PCI Biotech first half-year 2021 interim results

Oslo (Norway), 31 August 2021 PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first half-year 2021 results. Please find enclosed the report and presentation.
Highlights
fimaChem*The implementation of the…

Click here to view the original article.